Your browser doesn't support javascript.
loading
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Chen, Sing-Young; Beretta, Martina; Olzomer, Ellen M; Alexopoulos, Stephanie J; Shah, Divya P; Byrne, Frances L; Salamoun, Joseph M; Garcia, Christopher J; Smith, Greg C; Larance, Mark; Philp, Andrew; Turner, Nigel; Santos, Webster L; Cantley, James; Hoehn, Kyle L.
Afiliación
  • Chen SY; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Beretta M; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Olzomer EM; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Alexopoulos SJ; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Shah DP; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Byrne FL; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
  • Salamoun JM; Department of Chemistry and Virginia Tech Centre for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, USA.
  • Garcia CJ; Department of Chemistry and Virginia Tech Centre for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, USA.
  • Smith GC; School of Medical Science, University of New South Wales, Sydney, NSW 2052, Australia.
  • Larance M; Charles Perkins Centre, School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia.
  • Philp A; Charles Perkins Centre, School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia; Centre for Healthy Ageing, Centenary Institute, Camperdown, NSW 2050, Australia; School of Sport, Exercise and Rehabilitation Sciences, Faculty of Health, University of Technology Sydney, Sydne
  • Turner N; Cellular Bioenergetics Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia.
  • Santos WL; Department of Chemistry and Virginia Tech Centre for Drug Discovery, Virginia Tech, Blacksburg, VA 24061, USA.
  • Cantley J; School of Medicine, University of Dundee, Dundee DD1 4HN, UK.
  • Hoehn KL; School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: k.hoehn@unsw.edu.au.
Biochim Biophys Acta Mol Basis Dis ; 1870(1): 166908, 2024 01.
Article en En | MEDLINE | ID: mdl-37793464
ABSTRACT
Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders. Calorie restriction, semaglutide, rosiglitazone, and mitochondrial uncouplers have all demonstrated efficacy against one or more obesity-related metabolic disorders, but it currently remains unclear which therapeutic strategy best targets the combination of hyperglycaemia, liver fat, hypertriglyceridemia, and adiposity. Herein we performed a head-to-head comparison of 5 treatment interventions in the female db/db mouse model of severe metabolic disease. Treatments included ∼60 % calorie restriction (CR), semaglutide, rosiglitazone, BAM15, and niclosamide ethanolamine (NEN). Results showed that BAM15 and CR improved body weight and liver steatosis to levels superior to semaglutide, NEN, and rosiglitazone, while BAM15, semaglutide, and rosiglitazone improved glucose tolerance better than CR and NEN. BAM15, CR, semaglutide, and rosiglitazone all had efficacy against hypertriglyceridaemia. These data provide a comprehensive head-to-head comparison of several key treatment strategies for metabolic disease and highlight the efficacy of mitochondrial uncoupling to correct multiple facets of the metabolic disease milieu in female db/db mice.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico Límite: Animals Idioma: En Revista: Biochim Biophys Acta Mol Basis Dis Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico Límite: Animals Idioma: En Revista: Biochim Biophys Acta Mol Basis Dis Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Países Bajos